Detalles de la búsqueda
1.
Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.
Ther Drug Monit
; 46(1): 73-79, 2024 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37348074
2.
The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer.
Breast Cancer Res Treat
; 195(3): 325-331, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35974240
3.
Are novel oral oncolytics underdosed in obese patients?
Cancer Chemother Pharmacol
; 93(2): 129-136, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37906253
4.
Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors.
Cancer Med
; 13(12): e7302, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38899457
5.
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data.
Cancer Chemother Pharmacol
; 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38427065
6.
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.
Target Oncol
; 17(1): 53-59, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34894319
7.
Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer.
Clin Transl Sci
; 15(8): 1916-1925, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35775126
Resultados
1 -
7
de 7
1
Próxima >
>>